Octans Nutra Profile
Key Indicators
- Authorised Capital ₹ 2.50 M
as on 24-10-2024
- Paid Up Capital ₹ 1.81 M
as on 24-10-2024
- Company Age 32 Year, 8 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 3.68 Cr
as on 24-10-2024
- Revenue -85.80%
(FY 2023)
- Profit 61.24%
(FY 2023)
- Ebitda 95.17%
(FY 2023)
- Net Worth -4.00%
(FY 2023)
- Total Assets -11.03%
(FY 2023)
About Octans Nutra
The Corporate was formerly known as P.C.P.Pharmaceuticles Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.50 M and a paid-up capital of Rs 1.81 M.
The company currently has active open charges totaling ₹3.68 Cr.
Prasad Kudimuskula and Venkat Kudimuskula serve as directors at the Company.
- CIN/LLPIN
U24239TG1992PTC014079
- Company No.
014079
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
07 Apr 1992
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Octans Nutra?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Prasad Kudimuskula  | Director | 15-Apr-2011 | Current |
| Venkat Kudimuskula | Director | 15-Apr-2011 | Current |
Financial Performance of Octans Nutra.
Octans Nutra Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 85.8% decrease. The company also saw a substantial improvement in profitability, with a 61.24% increase in profit. The company's net worth dipped by a decrease of 4%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Octans Nutra?
In 2023, Octans Nutra had a promoter holding of 3.74% and a public holding of 96.26%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Hezen Pharmaceuticals LimitedActive 20 years 4 monthsPrasad Kudimuskula and Venkat Kudimuskula are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Syndicate Bank Creation Date: 01 Jul 2005 | ₹3.50 Cr | Open |
Syndicate Bank Creation Date: 20 Sep 2002 | ₹1.00 M | Open |
Syndicate Bank Creation Date: 15 Jan 2001 | ₹0.75 M | Open |
How Many Employees Work at Octans Nutra?
Unlock and access historical data on people associated with Octans Nutra, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Octans Nutra, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Octans Nutra's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
